| Business Summary | | Amylin
Pharmaceuticals,
Inc.
is
engaged
in
the
discovery,
development
and
commercialization
of
potential
drug
candidates
for
the
treatment
of
metabolic
disorders.
The
Company
is
developing
Symlin
(pramlintide
acetate)
for
the
treatment
of
diabetes
patients
who
use
insulin.
Symlin
is
a
synthetic
analog
of
the
human
hormone
amylin
that
was
invented
by
the
Company's
scientists.
The
Company
has
completed
clinical
testing
of
Symlin
that
it
believes
is
sufficient
to
support
United
States
Food
and
Drug
administration
approval
to
market
Symlin.
The
Company
submitted
a
New
Drug
Application
for
Symlin
to
the
FDA
in
December
2000,
and
this
application
was
filed
for
review
by
the
FDA
in
January
2001.
The
Company
anticipates
submitting
a
Marketing
Approval
Application
for
Symlin
to
regulatory
authorities
in
Europe
in
the
second
quarter
of
2001.
The
Company's
other
drug
candidates
are
AC2993,
AC3056
and
AC2993
LAR. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Amylin
Pharmaceuticals,
Inc.
is
engaged
in
the
discovery
and
development
of
potential
drug
candidates
for
the
treatment
of
metabolic
discorders.
For
the
six
months
ended
6/30/01,
the
company
reported
no
revenues.
Net
loss
increased
71%
to
$34.4
million.
Results
reflect
the
absence
of
any
collaborative
agreement
revenues.
Higher
losses
reflect
an
increase
in
development
cost
associated
with
the
AC2993
LAR
development
program
and
an
increase
in
employees. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Joseph Cook, Jr., 59 Chairman
and CEO | $588K | $190K | Daniel Bradbury, 39 Exec.
VP | 395K | 778K | Julia Brown, 54 Exec.
VP | -- | -- | Martin Brown, 54 Sr.
VP, Operations | 344K | 566K | Joann Data, M.D., Ph.D., 56 Sr.
VP of Regulatory Affairs and Quality Assurance | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|